These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35420123)

  • 41. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Nair P; Hasan T; Zaw KK; Allamuratova S; Ismailov A; Mendonca P; Bekbaev Z; Parpieva N; Singh J; Sitali N; Bermudez-Aza E; Sinha A
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):658-663. PubMed ID: 35768925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
    Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
    Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
    [No Abstract]   [Full Text] [Related]  

  • 44. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
    Wu HY; Tian Y; Wang XD; Sun JS; Fan LC; Chen MX; Li R; Chen Y
    J Paediatr Child Health; 2022 Jan; 58(1):116-121. PubMed ID: 34323328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India.
    Das M; Mamnoon F; Mansoor H; Meneguim AC; Singh P; Shah I; Ravi S; Kalon S; Hossain FN; Ferlazzo G; Isaakidis P; Furin J; Acharya S; Thakur HP
    Int J Tuberc Lung Dis; 2020 Dec; 24(12):1265-1271. PubMed ID: 33317670
    [No Abstract]   [Full Text] [Related]  

  • 46. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Decroo T; Aung KJM; Hossain MA; Gumusboga M; Ortuno-Gutierrez N; De Jong BC; Van Deun A
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34561288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study.
    Desai G; Purohit G; Borana H; Deokar K; Yogi S
    Monaldi Arch Chest Dis; 2022 May; 93(1):. PubMed ID: 35535455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB.
    Zabsonre I; Thi SS; Cox V
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1054-1057. PubMed ID: 33126938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Souleymane MB; Piubello A; Lawan IM; Hassane-Harouna S; Assao-Neino MM; Soumana A; Hamidou-Harouna Z; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Schwoebel V; Mamadou S; Lynen L; De Jong B; Van Deun A; Decroo T
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.
    Zhang Y; Jiang Y; Yu C; Li J; Shen X; Pan Q; Shen X
    Front Public Health; 2022; 10():990894. PubMed ID: 36187694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?
    Ndjeka N; Hughes J; Reuter A; Conradie F; Enwerem M; Ferreira H; Ismail N; Kock Y; Master I; Meintjes G; Padanilam X; Romero R; Schaaf HS; Riele JT; Maartens G
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1073-1080. PubMed ID: 33126942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial.
    Snobre J; Gasana J; Ngabonziza JCS; Cuella-Martin I; Rigouts L; Jacobs BK; de Viron E; Herssens N; Ntihumby JB; Klibazayre A; Ndayishimiye C; Van Deun A; Affolabi D; Merle CS; Muvunyi C; Sturkenboom MGG; Migambi P; de Jong BC; Mucyo Y; Decroo T
    BMJ Open; 2024 Jul; 14(7):e078379. PubMed ID: 39053960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.